Ionis Pharmaceuticals (IONS) Receivables (2009 - 2017)

Ionis Pharmaceuticals' Receivables history runs 9 years deep, the most recent figure standing at $125.9 million for Q4 2017.

• On a quarterly basis, Receivables rose 16.54% year-over-year to $125.9 million in Q4 2017; TTM through Dec 2017 was $125.9 million, a 16.54% increase from a year earlier, with the FY2017 full-year figure at $125.9 million, up 16.54% from the prior year.
• Receivables climbed to $125.9 million in Q4 2017 per IONS's latest filing, from $42.9 million in the prior quarter.
• Across five years, Receivables topped out at $125.9 million in Q4 2017 and bottomed at $746000.0 in Q2 2016.
• The 5-year median for Receivables is $12.0 million (2013), against an average of $28.7 million.
• Across the five-year window, Receivables tumbled 93.06% in 2015 and surged 6684.85% in 2017, its largest moves.
• Year by year, Receivables stood at $11.1 million in 2013, then tumbled by 64.84% to $3.9 million in 2014, then soared by 190.96% to $11.4 million in 2015, then soared by 851.42% to $108.0 million in 2016, then increased by 16.54% to $125.9 million in 2017.
• Per Business Quant, the three latest IONS Receivables figures stand at $125.9 million (Q4 2017), $42.9 million (Q3 2017), and $50.6 million (Q2 2017).